Cardiovascular
Tricuspid Regurgitation
1
Pipeline Programs↗
5
Active Trials↗
1
Companies Involved↗
Tricuspid Regurgitation is an early-stage landscape with 1 program across 1 company. The most active players are Medtronic Cardiovascular.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved
No programs
Analysis
Trial Status
7
clinical trials
Recruiting4 · 57%
Unknown status1 · 14%
Active, not recruiting1 · 14%
Completed1 · 14%
Clinical Trials
Trial Activity
7 trials
A Prospective, Multicenter, Randomized, Controlled Pivotal Trial to Evaluate the Safety and Effectiveness of Transcatheter Tricuspid Valve Repair With the Edwards PASCAL Transcatheter Valve Repair System and Optimal Medical Therapy (OMT) Compared to OMT Alone in Patients With Tricuspid Regurgitation
Recruiting·—·Preclinical·NCT04097145·1,270 enrolled
The Early Feasibility Study of the Transcatheter Tricuspid Valve Replacement System Transfemoral System
Recruiting·—·Preclinical·NCT04433065·150 enrolled
Enavogliflozin Outcome Trial in Functional Tricuspid Regurgitation
Active, not recruiting·—·Phase 3·NCT06027307·541 enrolled
Edwards PASCAL TrAnScatheter Valve RePair System in Tricuspid Regurgitation (CLASP TR) Early Feasibility Study
Completed·—·Preclinical·NCT03745313·65 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)